转移性黑色素瘤患者免疫治疗中[18F]FDG PET/CT反应监测的预后价值:不同代谢标准的比较
本研究纳入67例接受免疫检查点抑制剂治疗的转移性黑色素瘤患者,在基线、2周期后和4周期后行[18F]FDG PET/CT,采用EORTC、PERCIST及免疫治疗改良的PERCIMT、imPERCIST5和iPERCIST标准评估代谢反应,并与总生存期相关。2周期后仅PERCIMT显示代谢反应者生存显著更长;4周期后多种标准下反应者和疾病控制者生存显著更长;脾脏SUV比值较低者生存显著更长。
要点
- 2周期后仅PERCIMT标准显示代谢反应者总生存显著更长。
- 4周期后传统与免疫改良标准下反应者和疾病控制者总生存显著更长。
- 脾脏SUVmean与肝脏比值较低者总生存显著更长。
核心结论
- 转移性黑色素瘤患者4周期免疫检查点抑制剂后PET/CT代谢反应评估与总生存显著相关。
- 2周期后预后效能亦较高,尤其采用新型标准时。
- 脾脏葡萄糖代谢检查可能提供进一步预后信息。
研究设计与样本
- 纳入67例接受免疫检查点抑制剂治疗的转移性黑色素瘤患者。
- 在治疗前、2周期后和4周期后行[18F]FDG PET/CT。
- 采用EORTC、PERCIST及免疫治疗改良的PERCIMT、imPERCIST5和iPERCIST标准评估代谢反应。
- 计算脾脏与肝脏SUV比值(SLRmean、SLRmax)及骨髓与肝脏SUV比值(BLRmean、BLRmax)。
- PET/CT结果与总生存期进行相关性分析。
主要发现
- 中位随访61.5个月(95%CI 45.3–66.7个月)。
- 2周期后仅PERCIMT显示代谢反应者生存显著更长,其余标准各反应组间无显著生存差异。
- 4周期后传统与免疫改良多种标准下,代谢反应者和疾病控制者均观察到总生存延长趋势或显著延长。
- SLRmean较低者总生存显著更长。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the prognostic value of [18F]FDG PET/CT as part of response monitoring in metastatic melanoma patients treated with immune checkpoint inhibitors (ICIs). METHODS: Sixty-seven patients underwent [18F]FDG PET/CT before start of treatment (baseline PET/CT), after two cycles (interim PET/CT) and after four cycles of ICIs administration (late PET/CT). Metabolic response evaluation was based on the conventional EORTC and PERCIST criteria, as well as the newly introduced, immunotherapy-modified PERCIMT, imPERCIST5 and iPERCIST criteria. Metabolic response to immunotherapy was classified according to four response groups (complete metabolic response [CMR], partial metabolic response [PMR], stable metabolic disease [SMD], progressive metabolic disease [PMD]), and further dichotomized by response rate (responders = [CMR] + [PMR] vs. non-responders = [PMD] + [SMD]), and disease control rate (disease control = [CMR] + [PMR] + [SMD] vs. [PMD]). The spleen-to-liver SUV ratios (SLRmean, SLRmax) and bone marrow-to-liver SUV ratios (BLRmean, BLRmax) were also calculated. The results of PET/CT were correlated with patients' overall survival (OS). RESULTS: Median patient follow up [95% CI] was 61.5 months [45.3 - 66.7 months]. On interim PET/CT, the application of the novel PERCIMT demonstrated significantly longer survival for metabolic responders, while the rest criteria revealed no significant survival differences between the different response groups. Respectively on late PET/CT, both a trend for longer OS and significantly longer OS were observed in patients responding to ICIs with metabolic response and disease control after application of various criteria, both conventional and immunotherapy-modified. Moreover, patients with lower SLRmean values demonstrated significantly longer OS. CONCLUSION: In patients with metastatic melanoma PET/CT-based response assessment after four ICIs cycles is significantly associated with OS after application of different metabolic criteria. The prognostic performance of the modality is also high after the first two ICIs cycles, especially with employment of novel criteria. In addition, investigation of spleen glucose metabolism may provide further prognostic information.
引用
- Sachpekidis C, Weru V, Kopp-Schneider A, et al. The prognostic value of [18F]FDG PET/CT based response monitoring in metastatic melanoma patients undergoing immunotherapy: comparison of different metabolic criteria. Eur J Nucl Med Mol Imaging. 2023. PMID: 37099131. doi:10.1007/s00259-023-06243-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。